NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,690,000 shares of its common stock at a price to the public of $6.25 per share and…
Wed, 05 Mar 2025 05:29:00 GMT Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable ...
Wed, 05 Mar 2025 05:00:00 GMT All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date.
Wed, 05 Mar 2025 00:00:00 GMT NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases ...
Wed, 05 Mar 2025 00:00:00 GMT NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, ...
Mon, 03 Mar 2025 16:01:00 GMT In addition, Protara expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the public offering price ... This press release shall not constitute ...
